TY  - JOUR
AU  - Metro, Giulio
AU  - Di Maio, Massimo
PY  - 2018
TI  - Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
JF  - Translational Lung Cancer Research; Vol 7, Supplement 3 (September 26, 2018): Translational Lung Cancer Research1
Y2  - 2018
KW  - 
N2  - We agree with dr. Addeo and dr. Banna when they emphasize that the biology of non-small cell lung cancer (NSCLC) is complex, and that a single biomarker is probably not exhaustive in order to optimally predict (either positively or negatively) the potential efficacy of immune checkpoint inhibitors.
UR  - https://tlcr.amegroups.org/article/view/23045